Neuropeptides Drive Immune Tolerance by Generating Regulatory T Cells

Neuropeptides (VIP, alpha-MSH, CGRP) promote immune tolerance by generating regulatory T cells and suppressing inflammatory responses — a novel neuroimmune pathway for controlling autoimmunity and transplant rejection.

RPEP-01137ReviewModerate Evidence2006RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Neuropeptides including VIP, alpha-MSH/KPV, and CGRP promote immune tolerance through generation of regulatory T cells (Tregs) and suppression of pro-inflammatory dendritic cell activation — a novel immunosuppressive pathway with therapeutic potential for autoimmunity and transplantation.

Key Numbers

How They Did This

review study on neuropeptides, immune-function.

Why This Research Matters

Relevant for neuropeptides, immune-function, inflammation.

The Bigger Picture

Advances peptide research.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.
  • ?Clinical translation to evaluate.

Trust & Context

Key Stat:
Key finding Neuropeptides including VIP, alpha-MSH/KPV, and CGRP promote immune tolerance through generation of regulatory T cells (Tregs) and suppression of pro-
Evidence Grade:
moderate evidence.
Study Age:
Published in 2006.
Original Title:
A novel mechanism for immunosuppression: from neuropeptides to regulatory T cells.
Published In:
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 1(4), 400-9 (2006)
Database ID:
RPEP-01137

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

What was studied?

Neuropeptides Drive Immune Tolerance by Generating Regulatory T Cells

What was found?

Neuropeptides (VIP, alpha-MSH, CGRP) promote immune tolerance by generating regulatory T cells and suppressing inflammatory responses — a novel neuroimmune pathway for controlling autoimmunity and transplant rejection.

Read More on RethinkPeptides

Cite This Study

RPEP-01137·https://rethinkpeptides.com/research/RPEP-01137

APA

Ganea, Doina; Gonzalez-Rey, Elena; Delgado, Mario. (2006). A novel mechanism for immunosuppression: from neuropeptides to regulatory T cells.. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 1(4), 400-9.

MLA

Ganea, Doina, et al. "A novel mechanism for immunosuppression: from neuropeptides to regulatory T cells.." Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2006.

RethinkPeptides

RethinkPeptides Research Database. "A novel mechanism for immunosuppression: from neuropeptides ..." RPEP-01137. Retrieved from https://rethinkpeptides.com/research/ganea-2006-a-novel-mechanism-for

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.